42 results about "Anhydroicaritin" patented technology

The invention provides a method of converting icariin into anhydroicaritin by using a biological enzyme reaction so as to improve biological activity of icariin. According to the invention, under the action of naringinase, a reaction is carried out in an ethanol aqueous solution with a concentration of 30% to 70%, wherein, reaction temperature is 40 to 70 DEG C and reaction time is 1 to 30 h; glycosyl groups on hydroxy groups of icariin are cut off, and icariin is converted into anhydroicaritin with higher pharmacological activity; furthermore, machinability of icariin is improved, and the practical application scope of icariin can be enlarged.

The invention discloses a method for preparing herba epimedii low-glycoside components from herba epimedii. By means of an in-vitro enzymolysis technology, enzymolysis and desugaring are carried out on herba epimedii flavonoid polysaccharide obtained from alcohol extraction herba epimedii decoction pieces, and the herba epimedii low-glycoside components are obtained through conversion. The methodis high in enzymolysis conversion rate, easy and convenient to operate, environmentally friendly, economical and feasible. Polysaccharide substances, such as epmedin A, epmedin B, epmedin C and icariin, in herba epimedii total flavonoids can be completely enzymolyzed and converted into low-glycoside compounds, baohuoside II, sagittatoside A, sagittatoside B, rhamnose-based icarisid II, anhydroicaritin-3-O-rhamnose-dideoxyfuranose and baohuoside I. A stable composition structure ratio is achieved, so that the content of the herba epimedii low-glycoside components is increased.

The invention belongs to the technical field of medicines, and in particular relates to an anhydroicaritin tablet. The anhydroicaritin tablet contains anhydroicaritin, hydroxy propyl cellulose, fumed silica, diethylene glycol monoethyl ether and other pharmaceutically acceptable auxiliary materials. A preparation method comprises the following steps: dissolving anhydroicaritin and hydroxy propyl cellulose in diethylene glycol monoethyl ether, adding with fumed silica for adsorption, then uniformly mixing with the pharmaceutically acceptable auxiliary materials, and carrying out pressing by adopting a direct tableting technology. The medicine dissolution speed is high, the process is simple, a surfactant does not need to be added, and the micronization treatment is not needed. The acceleration test result shows that the prepared anhydroicaritin tablet is good in stability.

The invention provides application of anhydroicaritin in preparation of drugs used for treatment or prevention of diabetes, which belongs to the field of medicine. Anhydroicaritin is a Chinese herbal monomer extracted from the traditional Chinese medicine epimedium; when used for treating a patient with diabetes, anhydroicaritin can substantially reduce the contents of fasting blood-glucose and 2-h postprandial blood sugar and substantially lower down the rate of glycosylated hemoglobin and the content of microalbuminuria, and anhydroicaritin has a better treatment effect compared with those of an epimedium extract treatment group and an icariin treatment group. Anhydroicaritin has the advantages of definite therapeutic effects, small side effects, capacity of alleviating occurrence of diabetic complications and wide medical application prospects when used for treatment of diabetes.

The invention discloses application of anhydroicaritin in preparation of medicine curing or preventing myelodysplastic syndrome, and belongs to the field of medicine. The anhydroicaritin is traditional Chinese medicine monomer extracted from conventional traditional Chinese medicine epimedium, and can remarkably increase peripheral blood hemocyte amount and improve peripheral blood dyshaematopoiesis when the anhydroicaritin is used for curing a myelodysplastic syndrome patient; the curative effect of the anhydroicaritin is superior to that of an epimedium extractive and icariin; the anhydroicaritin is definite in curative effect and low in side effect when being used for curing myelodysplastic syndrome, and has a wide medical application prospect.

The invention discloses an anhydroicaritin crystal form A and an anhydroicaritin crystal form B and a preparation method thereof and belongs to the technical field of pharmaceutical chemistry. The preparation method of the anhydroicaritin crystal form A and the anhydroicaritin crystal form B is simple in process and high in conversion rate. The prepared crystal form A and crystal form B are single in crystal form and high in purity and has a significantly improved solubility curve when compared with amorphous powder, so that the stability of bioavailability is improved, and the druggability of the anhydroicaritin is facilitated. The structural formula of the anhydroicaritin is shown in the description.

The invention relates to an application of anhydroicaritin in preparation of an anti-fatigue medicine, which belongs to the medicine field. According to the invention, anhydroicaritin in the invention is a traditional Chinese medicine monomer extracted from traditional Chinese medicine epimeddium, the anti-fatigue effect of anhydroicaritin is better than that of epimedium flavone and icariin, and anhydroicaritin is suitable for treating fatigue due to various reasons, especially fatigue due to disease, cancer-related fatigue and chronic fatigue syndrome. The anhydroicaritin has the advantages of definite therapeutic effect for fatigue resistance and low side effect, and has wide medical application prospect.

The invention discloses NADH-containing (nicotinamide mononucleotide-containing) composition and preparation to improve climacteric symptoms and their preparation methods and applications and relatesto the field of medicine and health. The composition includes, by weight, 1-10 parts of NMN, 1-10 parts of secondary anhydroicaritin, 1-10 parts of chondroitin sulfate, 1-10 parts of ursodesoxycholicacid, 1-10 parts of sialic acid, 1-10 parts of S-adenosyl methionine, 1-10 parts of polygala root, 1-10 parts of DHA (docosahexaenoic acid), and 1-10 parts of gamma-aminobutyric acid. The components of the composition are in suitable ratio and can coact to all-directionally improve climacteric symptoms safely with no side effects. The preparation method of the preparation has a simple process flow, short process time and zero byproducts, is low in production cost and is easy to apply to large-scale production.

The invention relates to a preparation method for pure anhydroicaritin. Medical materials of herba epimedii of different producing areas serve as raw materials, and through extraction of herba epimedii flavonoid, hydrolyzation of hydrochloric acid and purification of the reversion phase efficient preparation chromatography, the pure anhydroicaritin with purity larger than 95% is obtained. The preparation method for the pure anhydroicaritin is simple in processing steps, high in purity, low in cost and capable of large-scale production.

The invention relates to a water soluble derivative of anhydroicaritin and a preparation method thereof, in particular to a flavonoid compound, a preparation method and application thereof. The derivative on the one hand retains the anhydroicaritin's pharmacological activity for treatment of coronary heart disease, cerebral ischemia and cerebral infarction, also improves the water solubility of anhydroicaritin, thus being widely applicable to solutions, injections or granules and other various pharmaceutical preparations for clinical use, and providing a new drug choice for clinical prevention and/or treatment of coronary heart disease, cerebral ischemia or cerebral infarction. In addition, the preparation method of the compound provided by the invention or its derivative or salt is simple, thus being convenient for industrial popularization and application.

The invention relates to a medicinal use of anhydroicaritin, especially relates to a use of anhydroicaritin in the preparation of myelosuppression prevention or treatment medicines, and belongs to the field of therapeutic activity of compounds. Anhydroicaritin has unexpected activity in immunity enhancement and hematopoiesis function promotion. Animal in vivo test confirms that the anhydroicaritin substantially improves the leucocyte quantity after chemotherapy, and especially the neutral granulocyte quantity. The anhydroicaritin is an active component capable of resisting the side effects of chemotherapy and improving the chemotherapy effect of tumors, and is of great significance for delaying the life time of cancer patients and improving the survival quality.

The invention discloses a novel application of prenylated flavonoid compound, and particularly relates to application of the prenylated flavonoid compound. The application includes that anhydroicaritin and 2'- hydroxyl-3'- alkene- anhydroicaritin are used as active agents for preparing medicines which resist osteoporosis and promote bone repair. An experiment result shows that the compound has a remarkable anti-osteoporosis effect, is low in toxicity and high in safety, and can be used as an anti-osteoporosis medicine.

The invention discloses a female health composition containing NMN (nicotinamide mononucleotide) and DHEA (dehydroepiandrosterone). The female health composition comprises main materials and auxiliarymaterials; the main materials include, by weight, 1-10 parts of NMN, 1-10 parts of DHEA, 1-10 parts of deglycosylated soybean isoflavones, 1-10 parts of sheep placenta extract, 1-10 parts of sialic acid, 1-10 parts of S-adenosyl methionine, and 1-10 parts of secondary anhydroicaritin. The formulation is reasonable and has good compatibility; the materials coact to provide excellent health effect;the composition is effective in repairing DNA, activating longevity proteins, defying age, delaying senility, enhancing physique, tonifying kidney and replenishing essence, invigorating spleen and benefiting qi, and nourishing and activating blood. The addition of NMN and DHEA to the formulation is provided for the first time; NMN and DHEA can cooperate with various specific medicinal auxiliariesto provide synergy, evidently improving the health effect of the composition. Also disclosed are a preparation containing the composition and a preparation process of the preparation. The compositionis applicable to ovary health products, blood-replenishing health products, endocrine regulation health products and climacteric syndrome delaying health products.

The invention discloses recombinant engineered escherichia coli pQE-sprha2-pbgl and a method of catalyzing icariin to produce anhydroicaritin by using the whole cells of the engineered escherichia coli. The strain co-expresses an alpha-L-rhamnosidase SPRHA2 and a beta-glucosidase PBGL through the form of polycistron, utilizes the method of whole-cell catalysis,takes an icariin crude extract as a substrate, and catalyzes the icariin to produce the anhydroicaritin through hydrolysis. Thus, the recombinant engineered escherichia coli strain containing the polycistron is constructed; and through the adoption of whole-cell catalysis, the conversion of the icariin to the anhydroicaritin can be directly realized, and the hydrolysis rate of the icariin is more than 98%.

The invention relates to an application of anhydroicaritin in preparation of medicine for treating anaemia, which belongs to the medicine field. The application of anhydroicaritin in preparation of medicine for treating anaemia solves the technical disadvantages of poor treatment effect of the current medicines and high price of the medicines. The invention also provides a medicine for treating anaemia by taking anhydroicaritin as active component. The pharmacological experiment displays that the anhydroicaritin has active treatment effect for aplastic anemia, anemia of inflammation, hemolytic anaemia, renal anemia or its combination. The anhydroicaritin for treating anaemia has the advantages of clear effect mechanism, clear composition, definite therapeutic effect and wide medical science application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an anhydroicaritin pharmaceutical composition and a preparation method thereof. The preparationmethod of the anhydroicaritin pharmaceutical composition comprises the following steps of: firstly, preparing an anhydroicaritin solid dispersion from anhydroicaritin, copovidone (PVP/VA), polyethylene glycol and triethyl citrate by adopting a hot-melt extrusion technology, and then uniformly mixing the anhydroicaritin solid dispersion with pharmaceutically acceptable auxiliary materials to prepare a preparation. According to the anhydroicaritin pharmaceutical composition prepared by the method, the solubility and the in-vitro dissolution rate of the anhydroicaritin are improved; and in addition, the anhydroicaritin pharmaceutical composition prepared by the method is stable in process, controllable in quality and convenient for industrial production.

The invention discloses a method for preparing high-purity herba epimedii essential oil and preparing anhydroicaritin by an enzyme method. According to the method, an ultrasonic technology is combined with a subcritical R134a fluid technology, a molecular distillation technology, a vacuum decompression boiling extraction technology, an enzyme immobilization technology, an enzyme one-pot catalysis technology, a macroporous resin purification technology, a recrystallization technology, a supercritical CO2 fluid drying technology and a full-automatic control technology, extraction, enzymolysis and purification are performed on the herba epimedii essential oil and herba epimedii total flavonoids under the synergistic effect of multiple raw materials, the herba epimedii oil and herba epimedii total flavonoids extracting solution are extracted continuously step by step in the same device, and the vacuum concentration is performed on the extracting solution to obtain herba epimedii total flavonoids extract, and the extract is converted from the crude product of the herba epimedii total flavonoids into a crude product of anhydroicaritin through enzymolysis. According to the method, the technology for producing the herba epimedii essential oil and the anhydroicaritin is high in resource utilization degree, high in product yield, high in product purity, low in residual solvent, low in energy consumption and small in environmental pollution and is suitable for industrial large-scale production.

The invention relates to a quality evaluation method of a five-ingredient capsule for warming and activating collaterals and eliminating arthralgia. 15 ingredients including coumarin, baicalin, epimedin C, icariin, cinnamic acid, wogonoside, cinnamyl aldehyde, baicalein, cinnamyl alcohol, 2-methoxycinnamyl aldehyde, wogonin, baohuoside I, dehydrated icariin, germacrone and pachymic acid are selected as quality markers of the compound; full-wavelength scanning detection is performed, and UHPLC quality evaluation is performed on WWCC (Wuwei Wuntong arthralgia-eliminating capsule) under two wavelengths of 203nm and 270nm; after the analysis method is established and verified, the 15 quality markers in the WWCC sample are quantitatively analyzed, a WWCC fingerprint spectrum under 270nm is constructed, and the overall quality evaluation of the WWCC sample is completed. The method provides a unique idea for WWCC comprehensive quality evaluation, and provides reference and demonstration effects for traditional Chinese medicine compound overall quality evaluation.

The invention belongs to the field of medicine, and particularly relates to application of anhydroicaritin, namely the application of the anhydroicaritin to preparation of a medicine for treating psoriasis. Animal tests show that the anhydroicaritin has a significant prevention and treatment effect on the psoriasis, can significantly improve psoriasis area and severity index (PASI) score and tissue morphological change of skin lesions of psoriasis, which proves that the anhydroicaritin has the application of treating the psoriasis. Compared with an existing medicine and method for treating the psoriasis, the novel application method disclosed by the invention can get an unexpected curative effect, the cure rate is high, and the novel application method is an innovation for treating the psoriasis.